Human arginase 1, a Jack of all trades?
- Published in:
- 3 Biotech, 2022, v. 12, n. 10, p. 1, doi. 10.1007/s13205-022-03326-9
- By:
- Publication type:
- Article
Works by Pande, Abhay H.
Results: 15
1
2
Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
- Published in:
- Medical Oncology, 2024, v. 41, n. 1, p. 1, doi. 10.1007/s12032-023-02245-w
- By:
- Publication type:
- Article
3
Role of paraoxonase 1 in organophosphate G-series nerve agent poisoning and future therapeutic strategies.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
4
Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
5
HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
- Published in:
- International Journal of Peptide Research & Therapeutics, 2022, v. 28, n. 2, p. 1, doi. 10.1007/s10989-021-10352-3
- By:
- Publication type:
- Article
6
Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
- Published in:
- APMIS, 2025, v. 133, n. 1, p. 1, doi. 10.1111/apm.13515
- By:
- Publication type:
- Article
7
Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192.
- Published in:
- PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0147999
- By:
- Publication type:
- Article
8
Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.
- Published in:
- Protein Science: A Publication of the Protein Society, 2013, v. 22, n. 12, p. 1799, doi. 10.1002/pro.2380
- By:
- Publication type:
- Article
9
Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
- Published in:
- FEBS Letters, 2006, v. 580, n. 6, p. 1691, doi. 10.1016/j.febslet.2006.02.006
- By:
- Publication type:
- Article
10
Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics.
- Published in:
- Immunology, 2024, v. 171, n. 4, p. 464, doi. 10.1111/imm.13743
- By:
- Publication type:
- Article
11
Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives.
- Published in:
- Scientific World Journal, 2014, p. 1, doi. 10.1155/2014/854391
- By:
- Publication type:
- Article
12
Broad-spectrum anti-cancer activity of fused human arginase variants.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 5, p. 531, doi. 10.1007/s10637-024-01466-8
- By:
- Publication type:
- Article
13
Development and characterization of fused human arginase I for cancer therapy.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 5, p. 652, doi. 10.1007/s10637-023-01387-y
- By:
- Publication type:
- Article
14
A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit.
- Published in:
- PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0018825
- By:
- Publication type:
- Article
15
Human arginase I: a potential broad-spectrum anti-cancer agent.
- Published in:
- 3 Biotech, 2023, v. 13, n. 5, p. 1, doi. 10.1007/s13205-023-03590-3
- By:
- Publication type:
- Article